Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT01062555Phase 2
Key facts
Phase 2, randomised, open-label trial of sirolimus in kidney transplantation, sponsored by University of Minnesota. Started Oct 2006; status: completed.
Reducing drug side effects is a key issue in transplantation. One class of drugs commonly used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely, toxicity to the transplanted kidney. In some patients, this toxicity is thought to be associated with loss of transplant function in those who have had their transplants for many years. The introduction of new immunosuppression medications however, has provided the opportunity to minimize or avoid CNIs, which may reduce the occurrence of toxicity to the kidney.
Beyond the preview
Full results, competitive context and analysis are in the Gosset platform.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT01062555.